BR112015014727A2 - composição imunogênica, uso de uma composição imunogênica, e, método para prevenir ou tratar a doença c.difficile - Google Patents
composição imunogênica, uso de uma composição imunogênica, e, método para prevenir ou tratar a doença c.difficileInfo
- Publication number
- BR112015014727A2 BR112015014727A2 BR112015014727A BR112015014727A BR112015014727A2 BR 112015014727 A2 BR112015014727 A2 BR 112015014727A2 BR 112015014727 A BR112015014727 A BR 112015014727A BR 112015014727 A BR112015014727 A BR 112015014727A BR 112015014727 A2 BR112015014727 A2 BR 112015014727A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- protein
- immunogenic composition
- cdtb
- clostridium difficile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1 / 1 resumo âcomposiãão imunogãnica, uso de uma composiãão imunogãnica, e, mãtodo para prevenir ou tratar a doenãa c.difficileâ a presente invenã§ã£o se refere a composiã§ãµes imunogãªnicas compreendendo proteãna clostridium difficile cdtb e/ou cdta isolada. em particular, a proteãna clostridium difficile cdtb isolada ã© adequadamente uma proteãna cdtb truncada compreendendo o domãnio de ligaã§ã£o de receptor ou uma proteãna cdtb mutada incapaz de fazer ligaã§ã£o com cdta, e a proteãna clostridium difficile cdta isolada ã© adequadamente uma proteãna cdtb truncada que nã£o compreende o domãnio de terminal c. em particular, a invenã§ã£o tambã©m se refere a proteãnas de fusã£o compreendendo uma proteãna cdta e a uma proteãna cdtb e tambã©m proteãnas de fusã£o entre uma proteãna b de toxina clostridium difficile isolada fundida a uma proteãna cdtb. a invenã§ã£o adicionalmente se refere a composiã§ãµes compreendendo fragmentos ou variantes da seq id no:3, seq id no:7, seq id no:16, seq id no:9, seq id no:51, seq id no:34, seq id no:36, seq id no:50, seq id no:14, seq id no:15, seq id no:46, seq id no:48, seq id no:52, seq id no:54, seq id no:40, seq id no:41 ou seq id no:42 ou seq id no:43 ou seq id no:44 ou seq id no:45.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1223342.5 | 2012-12-23 | ||
| GBGB1223342.5A GB201223342D0 (en) | 2012-12-23 | 2012-12-23 | Immunogenic composition |
| PCT/EP2013/077762 WO2014096393A1 (en) | 2012-12-23 | 2013-12-20 | Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015014727A2 true BR112015014727A2 (pt) | 2017-10-10 |
| BR112015014727B1 BR112015014727B1 (pt) | 2022-08-02 |
| BR112015014727B8 BR112015014727B8 (pt) | 2022-09-20 |
Family
ID=47682553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015014727A BR112015014727B8 (pt) | 2012-12-23 | 2013-12-20 | Composição imunogênica, vacina, e, uso de uma composição imunogênica |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9669083B2 (pt) |
| EP (1) | EP2934579B1 (pt) |
| JP (1) | JP6515036B2 (pt) |
| CN (1) | CN105120892B (pt) |
| AR (1) | AR094275A1 (pt) |
| AU (1) | AU2013366450A1 (pt) |
| BR (1) | BR112015014727B8 (pt) |
| CA (1) | CA2894951C (pt) |
| ES (1) | ES2748054T3 (pt) |
| GB (1) | GB201223342D0 (pt) |
| SG (1) | SG11201504701UA (pt) |
| WO (1) | WO2014096393A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014004896B1 (pt) | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
| PE20141029A1 (es) | 2011-04-22 | 2014-09-04 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| ES2704069T3 (es) * | 2011-12-08 | 2019-03-14 | Glaxosmithkline Biologicals Sa | Vacuna basada en toxinas de Clostridium difficile |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| BE1022949B1 (fr) * | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
| IL269258B2 (en) | 2017-03-15 | 2023-09-01 | Novavax Inc | Methods and compositions for inducing immune responses against Clostridium difficile |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| WO2019243307A1 (en) | 2018-06-19 | 2019-12-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| CN111793130B (zh) * | 2019-03-20 | 2021-09-14 | 华中农业大学 | 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用 |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2396652B1 (en) | 2009-02-11 | 2017-12-13 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| BR112014004896B1 (pt) * | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
-
2012
- 2012-12-23 GB GBGB1223342.5A patent/GB201223342D0/en not_active Ceased
-
2013
- 2013-12-20 CA CA2894951A patent/CA2894951C/en active Active
- 2013-12-20 JP JP2015548649A patent/JP6515036B2/ja active Active
- 2013-12-20 WO PCT/EP2013/077762 patent/WO2014096393A1/en active Application Filing
- 2013-12-20 CN CN201380073503.5A patent/CN105120892B/zh active Active
- 2013-12-20 ES ES13817931T patent/ES2748054T3/es active Active
- 2013-12-20 EP EP13817931.2A patent/EP2934579B1/en active Active
- 2013-12-20 AU AU2013366450A patent/AU2013366450A1/en not_active Abandoned
- 2013-12-20 BR BR112015014727A patent/BR112015014727B8/pt active Search and Examination
- 2013-12-20 US US14/653,989 patent/US9669083B2/en active Active
- 2013-12-20 AR ARP130105022A patent/AR094275A1/es unknown
- 2013-12-20 SG SG11201504701UA patent/SG11201504701UA/en unknown
-
2017
- 2017-05-15 US US15/595,651 patent/US20180043005A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2894951C (en) | 2023-05-09 |
| EP2934579A1 (en) | 2015-10-28 |
| CN105120892A (zh) | 2015-12-02 |
| EP2934579B1 (en) | 2019-08-07 |
| US20150313985A1 (en) | 2015-11-05 |
| US20180043005A1 (en) | 2018-02-15 |
| GB201223342D0 (en) | 2013-02-06 |
| AR094275A1 (es) | 2015-07-22 |
| JP6515036B2 (ja) | 2019-05-15 |
| JP2016504993A (ja) | 2016-02-18 |
| WO2014096393A1 (en) | 2014-06-26 |
| US9669083B2 (en) | 2017-06-06 |
| AU2013366450A1 (en) | 2015-07-23 |
| BR112015014727B8 (pt) | 2022-09-20 |
| CN105120892B (zh) | 2020-07-31 |
| BR112015014727B1 (pt) | 2022-08-02 |
| ES2748054T3 (es) | 2020-03-12 |
| SG11201504701UA (en) | 2015-07-30 |
| CA2894951A1 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015014727A2 (pt) | composição imunogênica, uso de uma composição imunogênica, e, método para prevenir ou tratar a doença c.difficile | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| CA2837395C (en) | Immunogenic composition comprising clostridium difficile toxin a and toxin b fusion protein | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| MY182429A (en) | Compositions relating to a mutant clostridium difficile toxin and methods thereof | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| MX359449B (es) | Conjugados de anticuerpo fármaco anti-cd70. | |
| BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| MX2012003058A (es) | Vacunas dirigidas a celulas de langerhans. | |
| EA201291138A1 (ru) | Способы, композиции и наборы для лечения нарушений, связанных с минерализацией матрикса | |
| BR112015017619A2 (pt) | formulação líquida, uso de uma formulação, e, kit | |
| MX2014004359A (es) | Proteina naglu humana recombinante y usos de la misma. | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| MY192248A (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
| MX2014010664A (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
| MX364623B (es) | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. | |
| BR112016015678B1 (pt) | Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica | |
| WO2010011952A3 (en) | Flip death effector domain derived peptides for inducing autophagy | |
| EP4011906A3 (en) | Lactase enzymes with improved properties | |
| AU2018277310A1 (en) | Aggrecan binding immunoglobulins | |
| MX365560B (es) | Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes. | |
| MX2016017094A (es) | Composicion inmunógena de clostridium difficile. | |
| MX2022007919A (es) | Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii). | |
| BR112013013960A2 (pt) | vacinas de malária baseadas em antígenos pré-eritrocíticos de p. falciparum | |
| AU2016203241A1 (en) | Immunogenic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2013, OBSERVADAS AS CONDICOES LEGAIS |
|
| B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2687 DE 05/07/2022. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2691 DE 02/08/2022 QUANTO AO TITULO. |